Next on tap for Meridian Bioscience‘s (NASDAQ:VIVO) illumigene molecular diagnostic testing platform is a test for Mycoplasma pneumonia, an infection of the lungs.
The illumigene Mycoplasma test is currently in clinical trials, according to a statement from Meridian announcing the Cincinnati-area company’s first-quarter earnings. Meridian plans to launch three to four new illumigene tests per year, CEO Jack Kraeutler said.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
After Mycoplasma, the next illumigene test Meridian is expected to release is for group A streptococcus, a type of bacteria often found on the throat or in the skin.
Cincinnati-area Meridian is betting big on the illumigene platform, which it says provides its hospital and laboratory customers with a simpler, cheaper option to test samples for certain types of bacteria without the use of expensive instrumentation.
Tests for C. difficile and group B streptococcus that utilize the platform have already been cleared by the U.S. Food and Drug Administration.
Meridian has completed 750 total “placements” worldwide of the illumigene technology, an increase of about 100 customers in the last 10 weeks, Kraeutler said.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
In the first quarter, Meridian’s net income grew 9 percent to $6.6 million, or 16 cents per diluted share. Net sales grew 8 percent to $40 million.
“While these results are positive, especially in a weak economy, we believe our potential for growth continues to increase,” Kraeutler said.
Meridian reaffirmed its previously issued full-year guidance of earnings per share between 85 cents and 89 cents, and net sales between $183 million and $192 million.
